NCT01111279View on ClinicalTrials.gov

Clinical Safety and Tolerability Study of gpASIT+TM and gpASIT+TM/Immunoregulating Adjuvant to Treat Seasonal Grass Pollen Rhinoconjunctivitis

PHASE1CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

March 31, 2010

Primary Completion Date

September 30, 2010

Study Completion Date

November 30, 2010

Conditions
Seasonal Allergic Rhinoconjunctivitis
Interventions
BIOLOGICAL

gpASIT+TM

1 subcutaneous injection every 7 days, during 29 days.

BIOLOGICAL

gpAST+TM/adjuvant

1 subcutaneous injection every 7 days, during 29 days

BIOLOGICAL

Placebo solution

1 subcutaneous injection every 7 days, during 29 days

Trial Locations (1)

3000

UZ Leuven, Gasthuisberg, Leuven

Sponsors

Lead Sponsor

BioTech Tools S.A.
All Listed Sponsors
lead

BioTech Tools S.A.

INDUSTRY